Bringing US Drug Manufacturing Back Home: Tariffs, Generics, and Policy Tools

US Reliance on Foreign Drug Manufacturing

• 🇨🇳 The US is significantly reliant on China for drug manufacturing, a dependence that has been documented since at least 2018.
• 🌍 This reliance is not unique to the US; it affects the entire world's supply of medicines.

Challenges with Generic Drug Imports

• ⚠️ China has historically not respected the FDA's role in ensuring proper manufacturing standards and has refused inspections.
• 🔬 The Department of Defense's generic drug testing program has revealed numerous manufacturing defects in products from uninspected plants in India and China.
• 💊 Generic drugs, which constitute 90% of medications used in the US, are particularly vulnerable due to smaller profit margins, making them harder to incentivize for domestic production.

Policy Tools for Reshoring Manufacturing

• 💰 A key policy tool discussed is leveraging US tax dollars for procurement, specifically by having the Department of Defense, HHS, and other agencies purchase generic drugs manufactured domestically by US-owned companies.
• 📈 This procurement strategy is believed to be a game-changer that could swiftly bring back domestic manufacturing of essential generic drugs.
• 🎯 The focus should be on bringing back manufacturing for essential generic drugs that are critical for national survival.

Addressing Cost and Middlemen

• 💲 While bringing manufacturing back may seem costly, the manufacturer's share of the total drug cost is often very small due to numerous middlemen.
• 🔍 It is crucial to examine how much middlemen profit from drug sales and redirect those funds back into US-based manufacturing.
• 💡 A personal anecdote highlights that a manufacturer might receive only $1 for a drug that costs a patient over $150, underscoring the issue of middlemen markups.

Public and Government Action

• 🗣️ Individuals can play a role by asking critical questions about the origin and manufacturing standards of their medications, as demonstrated by a constituent contacting the author.
• 🇺🇸 The federal government has begun taking slow steps since 2019-2020, but a concerted effort can accelerate the return of drug manufacturing to the United States.